Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Signing Ceremony of the "PARAMED Project"

 
Signing Ceremony of the "PARAMED Project": A Vital Reinforcement of the Public Health Sector in Lebanon
 

Under the patronage of H.E. Dr. Firass El Abiad, Mnister of Public Health, and in the presence of a delegation from the French Ministry of Health, an official signing ceremony for the "Project for Supporting the Healthcare Personnel Skills in the Public Sector in Lebanon (PARAMED)" took place in the conference room of the Ministry of Public Health (MOPH) in Jnah.  .

This project, co-financed by Agence Française de Developpement (AFD) and the IF! Foundation, and implemented by the European Institute for Cooperation and Development (IECD), aims to substantially strengthen the skills of healthcare professionals within Lebanon's public health structures.

In his speech, the Minister of Public Health, Dr. Firas El Abiad, emphasized: "The importance of this program lies in its expansion to include 12 public hospitals, after initially starting with four hospitals, with the aim of training healthcare professionals so they can provide the necessary services to our citizens, especially the most vulnerable segments of Lebanese society. This program is funded by the French Development Agency to the tune of six million euros and is implemented by the European Institute for Cooperation and Development in Lebanon." Minister Abiad continued by stating that: “This program would not have been possible without the support provided by France to Lebanon, particularly through the French Development Agency (AFD), which supports several projects in the health and education sectors. What is remarkable about this program is that it brings together the health and education sectors, with the goal of providing better healthcare services to all people on Lebanese territory.”

Mrs. Catherine Bonnaud, Country Director and Regional Director of AFD, declared that by investing in training and professional development of health workers, we strengthen not only individual capabilities, but also the resilience and effectiveness of the health system as a whole. This is a long-term investment in the health and well-being of all Lebanese citizens.

In a context of crisis affecting the Lebanese healthcare system, the PARAMED project represents a crucial initiative to improve the quality of care provided to the most vulnerable populations and facilitate access to it. The project includes, among other objectives, the establishment of training centers in 12 public hospitals and the implementation of ongoing training and refresher programs for recent graduates and existing hospital staff.
 
Mr. Vianney Basse, Director for Lebanon and the Middle East at IECD, emphasized the quality of the trust-based relationship between the Minister of Health, AFD, and IECD, and that this partnership is fully aligned with the Ministry’s 2030 Strategy. He recalled that IECD, whose mission is to support youth through vocational training projects, will strengthen its involvement in the health sector through PARAMED.

By strengthening the capacities of health professionals and promoting the employability of young men and women in the field of nursing, the PARAMED project aims to reach 4,200 healthcare workers and approximately 3 million patients. In doing so, it will help reduce gaps and improve the quality of healthcare in Lebanon.
    3
ATC Name B/G Ingredients Dosage Form Price
J07BB02 INFLUVAC B Grippal virus surface antigen 3strains - 15mcgx3strains/0.5ml Injectable suspension 573,821 L.L
J07CA06 INFANRIX IPV + HIB B Poliomyelitis virus type 3 inactivated(Prefilled syringe) - 32D.U., Poliomyelitis virus type 2 inactivated(Prefilled syringe) - 8D.U., Poliomyelitis virus type 1 inactivated(Prefilled syringe) - 40D.U., Bordetella pertussis antigen(Prefilled syringe) - toxoid 25mcg+filamentous haemaglutinin 25mcg+pertactin 8mcg, Tetanus toxoid (Prefilled syringe) - ?40IU, Diphtheria toxoid (Prefilled syringe) - ?30IU, H. Influenza type b polysaccharide(Vial) - 10mcg Injectable dry powder+suspension 3,014,239 L.L
J07CA09 INFANRIX HEXA B Diphteria toxoid purified (Prefilled syringe) - ?30IU/0.5ml, Tetanus toxoid purified (prefilled syringe) - ?40IU/0.5ml, Bordetella pertussis antigen (Prefilled syringe) - toxoid 25mcg+filamentous haemaglutinin 25mcg+pertactin 8mcg/0.5ml, Poliomyelitis virus type 1 antigen (prefilled syringe) - 40D.U./0.5ml, Poliomyelitis virus type 2 antigen(prefilled syringe) - 8D.U./0.5ml, Poliomyelitis virus type 3 antigen (prefilled syringe) - 32D.U./0.5ml, HBs Antigen (prefilled syringe) - 10mcg/0.5ml, H. Influenza type b polysaccharide (Vial) - 10mcg/0.5ml Injectable suspension 4,230,416 L.L
L01CE02 IRINOGEN G Irinotecan HCl - 100mg 100mg Injectable solution 5,239,642 L.L
L01CE02 IRINOGEN G Irinotecan HCl - 100mg 100mg Injectable solution 5,239,642 L.L
L01CE02 IRINOTECAN GP PHARM G Irinotecan HCl trihydrate - 100mg/5ml 100mg/5ml Injectable concentrated solution 5,239,642 L.L
L01CE02 IRINOTECAN HYDROCHLORIDE G Irinotecan HCl - 100mg/5ml 100mg/5ml Injectable concentrate for solution 2,085,644 L.L
L01CE02 IRINOTECAN THYMOORGAN G Irinotecan HCl - 100mg/5ml 100mg/5ml Injectable concentrated solution 6,111,796 L.L
L01CE02 IRNOCAM 100 G Irinotecan HCl - 100mg/5ml 100mg/5ml Injectable solution 7,320,947 L.L
L01CE02 IRINOTECAN THYMOORGAN G Irinotecan HCl - 40mg/2ml 40mg/2ml Injectable concentrated solution 2,123,271 L.L
L01CE02 IRNOCAM 40 G Irinotecan HCl - 40mg/2ml 40mg/2ml Injectable solution 908,694 L.L
L01CE02 IRINOTECAN THYMOORGAN G Irinotecan HCl - 40mg/2ml 40mg/2ml Injectable concentrated solution L.L
L01CE02 IRINOTECAN GP PHARM G Irinotecan HCl trihydrate - 100mg/5ml 100mg/5ml Injectable concentrated solution L.L
L01EA01 IMAREM G Imatinib (mesylate) - 400mg 400mg Tablet, film coated 64,682,117 L.L
L01EA01 IMATINIB GP PHARM G Imatinib - 400mg 400mg Tablet, coated 26,083,945 L.L
L01EA01 IMATINIB NEAPOLIS G Imatinib - 400mg 400mg Tablet, film coated 36,046,335 L.L
L01EA01 IMATINIB SHILPA MESYLATE G Imatinib - 400mg 400mg Tablet, film coated 21,518,059 L.L
L01EA01 IMATINIB SPC G Imatinib - 400mg 400mg Tablet, film coated 53,700,122 L.L
L01EA01 IMATINIB GP PHARM G Imatinib - 100mg 100mg Tablet, coated 26,083,945 L.L
L01EA01 IMATINIB NEAPOLIS G Imatinib - 100mg 100mg Tablet, film coated 31,085,276 L.L
L01EA01 IMATINIB NEAPOLIS G Imatinib - 100mg 100mg Tablet, film coated 16,144,207 L.L
L01EA01 IMATINIB SHILPA MESYLATE G Imatinib - 100mg 100mg Tablet, film coated 14,396,132 L.L
L01EA01 IMATINIB SPC G Imatinib - 100mg 100mg Tablet, film coated 29,473,181 L.L
L01EA05 ICLUSIG B Ponatinib - 15mg 15mg Tablet, film coated 103,555,839 L.L
L01EA05 ICLUSIG B Ponatinib - 45mg 45mg Tablet, film coated 207,092,651 L.L
L01EB01 IRESSA B Gefitinib - 250mg 250mg Tablet, fim coated 135,027,509 L.L
L01EF01 IBRANCE B Palbociclib - 75mg 75mg Capsule 172,164,216 L.L
L01EF01 IBRANCE B Palbociclib - 75mg 75mg Tablet, film coated 172,164,216 L.L
L01EF01 IBRANCE B Palbociclib - 100mg 100mg Capsule 172,164,216 L.L
L01EF01 IBRANCE B Palbociclib - 100mg 100mg Tablet, film coated 172,164,216 L.L
    3
Sitemap
© Copyrights reserved to Ministry of Public Health 2026